Iron overload inhibits osteogenesis and promotes adipogenesis in human bone marrow mesenchymal stem cells by producing reactive oxygen

doi:10.3969/j.issn.2095-4344.2016.14.004

Abstract

Abstract:

BACKGROUND: Iron overload as a new etiological factor participate in the pathogenesis of senile osteoporosis, but its mechanism remains unclear. But the mechanism of iron overload cause senile osteoporosis pathogenesis remains unclear. Osteogenic/adipogenic differentiation homeostasis of bone marrow mesenchymal stem cells (BMSCs) plays an important role in the maintenance of normal human bone mass, and its imbalance can lead to senile osteoporosis. Iron effects on the osteogenic/adipogenic differentiation of BMSCs remain unclear. Therefore, we clarify the role of iron overload in the pathogenesis of senile osteoporosis by studying the effect of iron overload on BMSCs osteogenic/adipogenic differentiation.
OBJECTIVE: To explore the effect of iron overload on the osteogenesis and adipogenesis of human BMSCs (hBMSCs) in vitro and to explicit the role of iron overload in the pathogenesis of senile osteoporosis.
METHODS: hBMSCs were isolated by using density gradient centrifugation method. Isolated cells were treated with normal saline as normal control group, treated with 10, 20, 30 μmol/L ferrous citrate to mimic iron overload conditions, or treated with 30 μmol/L ferrous citrate followed by 0.5 mmol/L N-acetylcysteine as an antioxidant.
RESULTS AND CONCLUSION: Iron overload did not remarkably inhibit the proliferation of hBMSCs, but it could promote the generation of reactive oxygen in hBMSCs. After treatment with ferrous citrate, the expression of c-Maf and Runx2 decreased, and the expression of peroxisome proliferator-activated receptor γ increased; moreover, formation of calcium nodules decreased, but lipid droplets were produced. N-acetylcysteine could inhibit the production of reactive oxygen and increase the expression of c-Maf induced by iron overload. These findings indicate that iron overload inhibits osteogenesis and promotes adipogenesis in hBMSCs through the generation of reactive oxygen. Meanwhile, c-Maf plays an essential role in the iron-overload induced differetiation imbalance.
中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

Key words: Iron, Cell Differentiation, Tissue Engineering

Han Yan-jiu, Liu Guo-hui, Liu Yong. Iron overload inhibits osteogenesis and promotes adipogenesis in human bone marrow mesenchymal stem cells by producing reactive oxygen[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(14): 2007-2014.

Figures/Tables 5

References

[1] Domrongkitchaiporn S, Sirikulchayanonta V, Angchaisuksiri P, et al. Abnormalities in bone mineral density and bone histology in thalassemia. J Bone Miner Res. 2003;18(9):1682-1688.

[2] Terpos E, Voskaridou E. Treatment options for thalassemia patients with osteoporosis. Ann N Y Acad Sci. 2010;1202:237-243.

[3] Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, et al. Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. J Clin Endocrinol Metab. 2003;88(8):3966-3972.

[4] Doyard M, Chappard D, Leroyer P, et al. Decreased bone formation explains osteoporosis in a genetic mouse model of hemochromatosiss. PLoS One. 2016; 11(2):e0148292.

[5] Kim BJ, Ahn SH, Bae SJ, et al. Iron overload accelerates bone loss in healthy postmenopausal women and middle-aged men: a 3-yearretrospective longitudinal study. J Bone Miner Res. 2012;27(11): 2279-2290.

[6] Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2014; 10(1):9-17.

[7] Tsay J, Yang Z, Ross FP, et al. Bone loss caused by iron overload in a murine model: importance of oxidative stress. Blood. 2010;116(14):2582-2589.

[8] Czekanska EM, Stoddart MJ, Richards RG, et al. In search of an osteoblast cell model for in vitro research. Eur Cell Mater. 2012;24:1-17.

[9] 田青,刘勇,李国庆,等.老年骨质疏松骨折血清铁水平的测定及临床意义[J].临床急诊杂志,2013,(3):10-16.

[10] Messer JG, Kilbarger AK, Erikson KM, et al. Iron overload alters iron-regulatory genes and proteins, down-regulates osteoblastic phenotype, and is associated with apoptosis in fetal rat calvaria cultures. Bone. 2009;45(5):972-979.

[11] Li GF, Pan YZ, Sirois P, et al. Iron homeostasis in osteoporosis and its clinical implications. Osteoporos Int. 2012;23(10):2403-2408.

[12] Vogiatzi MG, Macklin EA, Fung EB, et al. Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res. 2009;24(3):543-557.

[13] Yang Q, Jian J, Abramson SB, et al. Inhibitory effects of iron on bone morphogenetic protein 2-induced osteobl- astogenesis. J Bone Miner Res. 2011;26(6):1188-1196.

[14] Guan M, Yao W, Liu R, et al. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med. 2012;18(3):456-462.

[15] Nishikawa K, Nakashima T, Takeda S, et al. Maf promotes osteoblast differentiation in mice by mediating the age-related switch in mesenchymal cell differentiation. J Clin Invest. 2010;120(10):3455-3465.

[16] Veronesi F, Torricelli P, Borsari V, et al. Mesenchymal stem cells in the aging and osteoporotic population. Crit Rev Eukaryot Gene Expr. 2011;21(4):363-377.

[17] Singh L, Brennan TA1, Russell E1, et al. Aging alters bone-fat reciprocity by shifting in vivo mesenchymal precursor cell fate towards an adipogenic lineage. Bone. 2016;85:29-36.

[18] Shen J, James AW, Zhang X, et al. Novel Wnt regulator NEL-Like molecule-1 antagonizes adipogenesis and augments osteogenesis induced by bone morphogenetic protein 2. Am J Pathol. 2016;186(2):419-434.

[19] Ge C, Cawthorn WP, Li Y, et al. Reciprocal control of osteogenic and adipogenic differentiation by ERK/MAP kinase phosphorylation of Runx2 and PPARγ transcri- ption factors. J Cell Physiol. 2016;231(3): 587-596.

[20] Tang L, Chen Y, Pei F, et al. Lithium chloride modulates adipogenesis and osteogenesis of human bone marrow-derived mesenchymal stem cells. Cell Physiol Biochem. 2015;37(1):143-152.

[21] Chen Q, Shou P, Zheng C, et al. Fate decision of mesenchymal stem cells: adipocytes or osteoblasts? Cell Death Differ. 2016. in press.

[22] Li P, Yang YM, Sanchez S, et al. Deubiquitinase MYSM1 is essential for normal bone formation and mesenchymal stem cell differentiation. Sci Rep. 2016;6:22211.

[23] Chen PM, Lin CH, Li NT, et al. c-Maf regulates pluripotency genes, proliferation/self-renewal, and lineage commitment in ROS-mediated senescence of human mesenchymal stem cells. Oncotarget. 2015; 6(34):35404-35418.

[24] Saidak Z, Haÿ E, Marty C, et al. Strontium ranelate rebalances bone marrow adipogenesis and osteoblastogenesis in senescent osteopenic mice through NFATc/Maf and Wnt signaling. Aging Cell. 2012;11(3):467-474.

[25] Gennari L, Rotatori S, Bianciardi S, et al. Treatment needs and current options for postmenopausal osteoporosis. Expert Opin Pharmacother. 2016. in press.

[26] Karasik D, Rivadeneira F, Johnson ML. The genetics of bone mass and susceptibility to bone diseases. Nat Rev Rheumatol. 2016. in press.

[27] Gibon E, Lu L, Goodman SB. Aging, inflammation, stem cells, and bone healing. Stem Cell Res Ther. 2016;7(1):44.

[28] Loi F, Córdova LA, Pajarinen J, et al. Inflammation, fracture and bone repair. Bone. 2016;86:119-130.

[29] Lindsay R, Krege JH, Marin F, et al. Teriparatide for osteoporosis: importance of the full course. Osteoporos Int. 2016. in press.

[30] Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med. 2016 ;374(3):254-262.

[31] Li GF, Pan YZ, Sirois P, et al. Iron homeostasis in osteoporosis and its clinical implications. Osteoporos Int. 2012;23(10):2403-2408.

[32] Zhao L, Wang Y, Wang Z, et al. Effects of dietary resveratrol on excess-iron-induced bone loss via antioxidative character. J Nutr Biochem. 2015;26(11): 1174-1182.

[33] Chen B, Li GF, Shen Y, et al. Reducing iron accumulation: A potential approach for the prevention and treatment of postmenopausal osteoporosis. Exp Ther Med. 2015;10(1):7-11.

[34] Xiao W, Beibei F, Guangsi S, et al. Iron overload increases osteoclastogenesis and aggravates the effects of ovariectomy on bone mass. J Endocrinol. 2015;226(3):121-134.

[35] Tournis S, Dede AD, Savvidis C, et al. Effects of teriparatide retreatment in a patient with β-thalassemia major. Transfusion. 2015;55(12):2905-2910.

[36] Wong P, Polkinghorne K, Kerr PG, et al. Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria. Bone. 2016;85:55-58.

[37] Rossi F, Perrotta S, Bellini G, et al. Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels. Haematologica. 2014;99(12):1876-1884.

[38] Chen B, Yan YL, Liu C, et al. Therapeutic effect of deferoxamine on iron overload-induced inhibition of osteogenesis in a zebrafish model. Calcif Tissue Int. 2014;94(3):353-360.

[39] Zhou J, Ye S, Fujiwara T, et al. Steap4 plays a critical role in osteoclastogenesis in vitro by regulating cellular iron/reactive oxygen species (ROS) levels and cAMP response element-binding protein (CREB) activation. J Biol Chem. 2013;288(42):30064-30074.

[40] Wong P, Fuller PJ, Gillespie MT, et al. Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures. Osteoporos Int. 2013;24(7):1965-1971.

[41] Kim MK, Lee JW, Baek KH, et al. Endocrinopathies in transfusion-associated iron overload. Clin Endocrinol (Oxf). 2013;78(2):271-277.

[42] Lu W, Zhao M, Rajbhandary S, et al. Free iron catalyzes oxidative damage to hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload patients. Eur J Haematol. 2013;91(3):249-261.

[43] Zhao GY, Zhao LP, He YF, et al. A comparison of the biological activities of human osteoblast hFOB1.19 between iron excess and iron deficiency. Biol Trace Elem Res. 2012;150(1-3):487-495.

[44] Messer JG, Kilbarger AK, Erikson KM, et al. Iron overload alters iron-regulatory genes and proteins, down-regulates osteoblastic phenotype, and is associated with apoptosis in fetal rat calvaria cultures. Bone. 2009;45(5):972-979.

[45] Singh L, Brennan TA, Russell E, et al. Aging alters bone-fat reciprocity by shifting in vivo mesenchymal precursor cell fate towards an adipogenic lineage. Bone. 2016;85:29-36.

[46] Zhang Y, Ma C, Liu X, et al. Epigenetic landscape in PPARγ2 in the enhancement of adipogenesis of mouse osteoporotic bone marrow stromal cell. Biochim Biophys Acta. 2015;1852(11):2504-2516.

[47] Simann M, Schneider V, Le Blanc S, et al. Heparin affects human bone marrow stromal cell fate: Promoting osteogenic and reducing adipogenic differentiation and conversion. Bone. 2015;78:102-113.

[48] Watt J, Schlezinger JJ. Structurally-diverse, PPARγ-activating environmental toxicants induce adipogenesis and suppress osteogenesis in bone marrow mesenchymal stromal cells. Toxicology. 2015;331:66-77.

[49] Li CJ, Cheng P, Liang MK, et al. MicroRNA-188 regulates age-related switch between osteoblast and adipocyte differentiation. J Clin Invest. 2015;125(4): 1509-1522.

[50] Tan XL, Zhang YH, Cai JP, et al. 5-(Hydroxymethyl)-2-furaldehyde inhibits adipogenic and enhances osteogenic differentiation of rat bone mesenchymal stem cells. Nat Prod Commun. 2014; 9(4):529-532.

[51] Lee DS, Choung HW, Kim HJ, et al. NFI-C regulates osteoblast differentiation via control of osterix expression. Stem Cells. 2014;32(9):2467-2479.

[52] Soucie EL, Weng Z, Geirsdóttir L, et al. Lineage-specific enhancers activate self-renewal genes in macrophages and embryonic stem cells. Science. 2016;351(6274):aad5510.

[53] Pellegrino S, Ronda L, Annoni C, et al. Molecular insights into dimerization inhibition of c-Maf transcription factor. Biochim Biophys Acta. 2014; 1844(12):2108-2115.

[54] Wende H, Lechner SG, Cheret C, et al. The transcription factor c-Maf controls touch receptor development and function. Science. 2012;335 (6074):1373-1376.

[55] Su W, Hopkins S, Nesser NK, et al. The p53 transcription factor modulates microglia behavior through microRNA-dependent regulation of c-Maf. J Immunol. 2014;192(1):358-366.

[56] McCauley LK. c-Maf and you won't see fat. J Clin Invest. 2010;120(10):3440-3442.

[57] Tseng KY, Lin S. Zinc finger factor 521 enhances adipogenic differentiation of mouse multipotent cells and human bone marrowmesenchymal stem cells. Oncotarget. 2015;6(17):14874-14884.

[58] Ahmadian M, Suh JM, Hah N, et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. 2013;19(5):557-566.

[59] Li R, Liang L, Dou Y, et al. Mechanical strain regulates osteogenic and adipogenic differentiation of bone marrow mesenchymal stem cells. Biomed Res Int. 2015;2015:873251.